Salbutamol Tolerance Onset
Overview
Overuse of inhaled bronchodilator beta agonist medication results in a loss of effectiveness (i.e. tolerance). This has been shown for the short acting beta agonist salbutamol and the long acting beta agonist salmeterol. Tolerance to salmeterol is present within 24 hours. The onset of tolerance to salbutamol is not known.
Full Title of Study: “Salbutamol: Tolerance to Bronchoprotection vs. Methacholine: Time Course of Onset”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Basic Science
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Study Primary Completion Date: March 2012
Interventions
- Drug: salbutamol
- 200mcg twice daily for a total of 7 doses
- Drug: Placebo
- 200mcg twice a day for a total of 7 doses (3.5 days).
Arms, Groups and Cohorts
- Active Comparator: salbutamol
- Placebo Comparator: placebo
- 200mcg twice daily for a total of 7 doses
Clinical Trial Outcome Measures
Primary Measures
- Airway responsiveness as a measure of salbutamol bronchoprotection
- Time Frame: ten minutes post 200mcg salbutamol on day 1
- Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
- Airway responsiveness as a measure of salbutamol bronchoprotection
- Time Frame: ten minutes post 200mcg salbutamol on day 3
- Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
- Airway responsiveness as a measure of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
- Time Frame: ten minutes post 200mcg salbutamol on day 5
- Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
- Airway responsiveness as a measure of salbutamol bronchoprotection
- Time Frame: ten minutes post 200mcg salbutamol on day 7
- Regular use of salbutamol results in loss of bronchoprotection. The primary outcome is to determine the onset of this tolerance.
Participating in This Clinical Trial
Inclusion Criteria
- male or female – 18 to 65 years of age – non smoker – beta agonist naive for at least 14 days – baseline FEV1 at least 70% predicted – no respiratory tract infection or allergen exposure (if atopic) within 4 weeks of visit 1 Exclusion Criteria:
- poorly controlled asthma – pregnant or lactating women
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 65 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University of Saskatchewan
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Donald W Cockcroft, MD, Principal Investigator, University of Saskatchewan
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.